Anthrax vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Anthrax vaccine
Accession Number
DB11003
Description

Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium [FDA Label].

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Anthrax vaccine adsorbed
  • Bacillus anthracis inactivated antigen
  • Bacillus anthracis strain V770-NP1-R antigen
  • Bacillus anthracis strain V770-NP1-R antigens
  • Bacillus anthracis strain V770-NP1-R filtrate (attenuated) antigen
  • Bacillus anthracis strain V770-NP1-R filtrate antigen
External IDs
  • RPA102

Pharmacology

Indication
Not Available
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Anthrax vaccine is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Anthrax vaccine is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Anthrax vaccine is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Anthrax vaccine is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Anthrax vaccine is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Altretamine.
AmantadineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Amantadine.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BioThraxInjection, suspension100 ug/1mLIntramuscular; SubcutaneousEmergent BioDefense Operations Lansing, LLC1970-11-04Not applicableUS flag
BioThraxSuspension50 mcgIntramuscular; SubcutaneousEmergent Biodefense Operations Lansing LlcNot applicableNot applicableCanada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
873OI62848
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911075
RxNav
1368371
Wikipedia
Anthrax_vaccine
FDA label
Download (363 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionBacillus Anthracis (Anthrax)1
4CompletedPreventionHealthy Volunteers1
3CompletedPreventionAnthrax1
3CompletedTreatmentAnthrax1
2CompletedPreventionAnthrax3
2CompletedTreatmentAnthrax1
2TerminatedPreventionBacillus Anthracis (Anthrax)1
1Active Not RecruitingPreventionAnthrax1
1Active Not RecruitingPreventionHealthy Volunteers1
1CompletedPreventionAnthrax1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular; Subcutaneous100 ug/1mL
SuspensionIntramuscular; Subcutaneous50 mcg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:05 / Updated on June 12, 2020 11:42

Pbdb medl 1